MIM
RGLS

MetLife Investment Management’s Regulus Therapeutics RGLS Stock Holding History

MetLife Investment Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,779
Closed -$30K – 2882
2024
Q2 		$30K Buy
+16,779
New +$38.9K ﹤0.01% 2849

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's RGLS Position: Q3 2024 in Review

MetLife Investment Management sold out of Regulus Therapeutics (RGLS) in Q3 2024, closing a stake of 16,779 shares — an estimated $30K sold.

MetLife Investment Management first reported a position in RGLS in Q2 2024 and held it in 1 quarter. The position peaked at $30K in Q2 2024. 70 funds tracked by Wall St. Rank hold RGLS as of Q3 2024.

  • MetLife Investment Management reported no remaining Regulus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 16,779 Regulus Therapeutics shares in Q3 2024, an estimated $30K.
  • MetLife Investment Management first reported a position in Regulus Therapeutics in Q2 2024 and held it in 1 quarter.
  • MetLife Investment Management's Regulus Therapeutics position peaked at $30K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.